{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:39:13Z","timestamp":1760146753552,"version":"build-2065373602"},"reference-count":34,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Treatment of CV risk factors, such as cholesterol level, represents one of the main goals to reduce atherosclerotic burden. The aim of this study was to investigate the prescriptive appropriateness of cholesterol-lowering drugs among patients who experienced an atherosclerotic CV disease (ASCVD). Methods: We investigated 155 patients who underwent cardiac rehabilitation in 2020. The European Society of Cardiology (ESC) 2021 guidelines on CV disease prevention and 2019 ESC Guidelines on dyslipidemias were followed to detect the appropriateness of prescription. SCORE2 and SCORE2-OP risk estimations were used to detect patients\u2019 CV risk profiles. Patients were divided into three groups: 1 (n = 118) patients admitted for their first CV event, 2A (n = 18) patients who experienced a previous CV event years before, and 2B (n = 19) patients admitted for a new event with a previous CV event 2 years before. Low-density lipoprotein (LDL) cholesterol level was detected at the time of admission to the hospital, during cardiac rehabilitation, and at the first visit after rehabilitation. Results: The statistics for our study participants, with a mean age of 66.1 years, were: 72.4% overweight\/obese, 63.9% diabetic, 72.5% smokers, 93.0% hypertensives, and 91.7% had dyslipidemias. In group 1, only 5.1% had a low\/moderate risk, 44.1% presented a high risk, and 50.8% a very high risk according to calculators. The average LDL levels were 115.8 mg\/dL (2.99 mol\/L) upon admission to the hospital, 66.4 mg\/dL (1.72 mmol\/L) at the time of cardiac rehabilitation, and 64.8 mg\/dL (1.67 mmol\/L) at the subsequent medical visit. In the overall group, only 36.0% had LDL &lt; 55 mg\/dL (1.42 mmol\/L). In group 1, 79.4% were treated with high-intensity statin alone or plus ezetimibe; in group 2A, the percentage increased up to 87.5%, while group 2B 33.4% was treated with high-intensity statin plus ezetimibe and 33.3% were treated with PCSK9 inhibitors. Conclusions: This retrospective study confirms the importance of properly calculating CV risk profiles. The main limitations for the efficacy of lipid-lowering drugs were: patient\u2019s compliance, drugs side effects, lifestyle habits, and collaboration with a general practitioner.<\/jats:p>","DOI":"10.3390\/jcm13247505","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T11:17:20Z","timestamp":1733829440000},"page":"7505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescriptive Appropriateness and Efficacy of Cholesterol-Lowering Drugs in a Secondary Prevention Setting\u2014A Retrospective Analysis from Two Italian Cardiac Rehabilitation Centers"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-4738","authenticated-orcid":false,"given":"Francesca","family":"Saladini","sequence":"first","affiliation":[{"name":"Cardiology Unit, Cittadella Town Hospital, 35013 Cittadella, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Baggio","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Camposampiero Town Hospital, 35012 Camposampiero, Italy"},{"name":"Cardiology Unit, Camposampiero Town Hospital, 35012 Camposampiero, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Marcato","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Camposampiero Town Hospital, 35012 Camposampiero, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Campisi","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Camposampiero Town Hospital, 35012 Camposampiero, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Verlato","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cittadella Town Hospital, 35013 Cittadella, Italy"},{"name":"Pharmacology Unit, Camposampiero Town Hospital, 35012 Camposampiero, Italy"},{"name":"Cardiology Unit, Camposampiero Town Hospital, 35012 Camposampiero, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Pasquetto","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cittadella Town Hospital, 35013 Cittadella, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-2904","authenticated-orcid":false,"given":"Emanuele","family":"Bertaglia","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Camposampiero Town Hospital, 35012 Camposampiero, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Povolo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cittadella Town Hospital, 35013 Cittadella, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Buja","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cittadella Town Hospital, 35013 Cittadella, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7441","authenticated-orcid":false,"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[{"name":"Pharmacology, University of Padova, 35131 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"ref_1","unstructured":"WHO CVD Risk Chart Working Group (2019). World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. Lancet Glob. Health, 7, e1332\u2013e1345."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: Epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_6","first-page":"e698","article-title":"2018 AHA\/ACC Guideline for the Management of Adults with Congenital Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Stout","year":"2019","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 26, S5\u2013S20.","DOI":"10.2337\/diacare.26.2007.S5"},{"key":"ref_12","first-page":"s176","article-title":"Obesity: Definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehaa605","article-title":"2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease","volume":"42","author":"Pelliccia","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5694\/j.1326-5377.2002.tb04344.x","article-title":"Applying evidence-based guidelines improves use of colonoscopy resources in patients with a moderate risk of colorectal neoplasia","volume":"176","author":"Bampton","year":"2002","journal-title":"Med. J. Aust."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1177\/2047487316667784","article-title":"Lifestyle and risk factor management in people at high risk of cardiovascular disease: A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.21037\/cdt.2017.04.06","article-title":"The EUROASPIRE surveys: Lessons learned in cardiovascular disease prevention","volume":"7","author":"Kotseva","year":"2017","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pcad.2023.10.006","article-title":"Characteristics of patients with recurrent acute myocardial infarction after MINOCA","volume":"81","author":"Ciliberti","year":"2023","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease","volume":"60","author":"Ference","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both","volume":"65","author":"Ference","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","first-page":"264","article-title":"Impiego degli inibitori di PCSK9 nel paziente a rischio cardiovascolare proibitivo: Il punto di vista del cardiologo interventista sulla rapidit\u00e0 d\u2019azione, efficacia, appropriatezza prescrittiva e rimborsabilit\u00e0 farmacologica [PCSK9 inhibitor use in high cardiovascular risk patients: An interventionalist\u2019s overview on efficacy, current recommendations and factual prescription]","volume":"21","author":"Masiero","year":"2020","journal-title":"G. Ital. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40119-024-00384-3","article-title":"Asia-Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study","volume":"13","author":"Tse","year":"2024","journal-title":"Cardiol. Ther."},{"key":"ref_25","unstructured":"(2023, January 13). Available online: https:\/\/www.aifa.gov.it\/-\/modifica-registri-di-monitoraggio-repatha-e-praluent-inibitori-di-pcsk-9-."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients with Hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_28","unstructured":"(2023, January 13). Nilemdo, Determina n.20\/2023 del 13 Gennaio 2023. Gazzetta Ufficiale Serie Generale n.22 del 27-01-2023. Available online: https:\/\/www.gazzettaufficiale.it\/gazzetta\/serie_generale\/caricaDettaglio?dataPubblicazioneGazzetta=2023-01-27&numeroGazzetta=22."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.athplu.2024.10.001","article-title":"Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials","volume":"58","author":"Iannuzzo","year":"2024","journal-title":"Atheroscler. Plus"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jch.13130","article-title":"Effects of aerobic interval training on arterial stiffness and microvascular function in patients with metabolic syndrome","volume":"20","author":"Pallares","year":"2018","journal-title":"J. Clin. Hypertens."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.109.894584","article-title":"Arterial structure and function after recovery from the metabolic syndrome: The cardiovascular risk in Young Finns Study","volume":"121","author":"Koskinen","year":"2010","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"L\u00f6dding, P., Beyer, S., P\u00f6kel, C., K\u00fcck, M., Leps, C., Radziwolek, L., Kerling, A., Haufe, S., Schulze, A., and Kwast, S. (2024). Adherence to long-term telemonitoring-supported physical activity in patients with chronic heart failure. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-70371-0"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e39593","DOI":"10.2196\/39593","article-title":"Effectiveness of mHealth Interventions in the Control of Lifestyle and Cardiovascular Risk Factors in Patients After a Coronary Event: Systematic Review and Meta-analysis","volume":"10","year":"2022","journal-title":"JMIR mHealth uHealth"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e29928","DOI":"10.2196\/29928","article-title":"mHealth Interventions for Lifestyle and Risk Factor Modification in Coronary Heart Disease: Randomized Controlled Trial","volume":"9","author":"Bae","year":"2021","journal-title":"JMIR mHealth uHealth"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:51:14Z","timestamp":1760115074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":34,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247505"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247505","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}